Sales grew 6% at constant exchange rates in H1 2026, driven by strong demand for innovative medicines and diagnostics, while Swiss franc appreciation weighed on reported results. Regulatory momentum was strong with five US FDA Priority Reviews and several key product launches.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.